Leerink Partnrs Issues Negative Forecast for CSTL Earnings

Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Investment analysts at Leerink Partnrs reduced their Q2 2025 earnings estimates for shares of Castle Biosciences in a research report issued to clients and investors on Monday, May 5th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.44) per share for the quarter, down from their previous estimate of ($0.33). The consensus estimate for Castle Biosciences' current full-year earnings is $0.44 per share. Leerink Partnrs also issued estimates for Castle Biosciences' Q3 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.44) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.71) EPS and FY2027 earnings at ($1.40) EPS.

Several other equities research analysts also recently weighed in on CSTL. Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the stock a "buy" rating in a report on Friday, March 28th. Canaccord Genuity Group reduced their price objective on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Lake Street Capital lowered their target price on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $37.50.

Castle Biosciences Trading Down 2.4 %

NASDAQ CSTL traded down $0.42 during trading on Thursday, hitting $16.79. The stock had a trading volume of 380,690 shares, compared to its average volume of 402,443. The firm has a 50 day moving average price of $19.83 and a 200 day moving average price of $25.61. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences has a twelve month low of $15.70 and a twelve month high of $35.84. The company has a market capitalization of $484.76 million, a PE ratio of 83.95 and a beta of 1.19.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The business had revenue of $87.99 million during the quarter, compared to analysts' expectations of $80.40 million.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $19.52, for a total value of $41,577.60. Following the transaction, the insider now directly owns 78,335 shares in the company, valued at $1,529,099.20. This represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 27,454 shares of company stock valued at $553,030. 6.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Castle Biosciences by 11.7% during the 1st quarter. Vanguard Group Inc. now owns 2,047,565 shares of the company's stock worth $40,992,000 after acquiring an additional 215,030 shares in the last quarter. Harbour Investments Inc. acquired a new stake in shares of Castle Biosciences during the first quarter worth about $50,000. XTX Topco Ltd purchased a new stake in shares of Castle Biosciences in the 1st quarter valued at about $393,000. Mackenzie Financial Corp boosted its position in shares of Castle Biosciences by 30.6% in the 1st quarter. Mackenzie Financial Corp now owns 27,460 shares of the company's stock valued at $550,000 after purchasing an additional 6,440 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Castle Biosciences in the 1st quarter valued at about $235,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.